


Practitioner's Docket No. 741135-000010

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SIFFERT, W. Group: Not yet assigned
Application No.: Not yet assigned Examiner: Not yet assigned
Filed: Herewith
(Continuation of 09/180,783 – Filed: 16 November 1998)
For: THE USE OF A GENETIC MODIFICATION IN THE GENE FOR
HUMAN G PROTEIN β 3 SUBUNIT FOR THE DIAGNOSIS OF
DISEASES

JCE72 U.S. PTO
09/836697
04/16/01

CERTIFICATE OF MAILING	
I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EL565099793US in an envelope addressed to Box Patent Application Assistant Commissioner of Patents, Washington, D.C. 20231.	
Date: 16 April 2001	 Nicole M. Gignac

Assistant Commissioner for Patents
Washington D.C. 20231

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References CA - CG, cited in the attached Form PTO-1449.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or

In re application of:
Application No.:
Filed:

SHIPT, W.
Not yet assigned
Herewith

Group: Not yet assigned
Examiner: Not yet assigned

- (2) within three months of the mailing date of the PCT
International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a
Final Rejection or Notice of Allowance, and the requisite
Certification or fee under Rule 1.17(p), namely **\$240.00**, is
included herein; or
- (4) after the mailing date of a **Final Rejection or Notice of
Allowance** but before the payment of the **Issue Fee**, and the
requisite Certification, petition, and petition fee are included
herein.

It is respectfully requested that each of the documents shown on the attached Form(s) PTO-1449
be made of record in this application. Copies of these documents (CHECK ONE):

- are enclosed herewith; or
- X have been cited in the parent application, and are thus not being
resubmitted herein.


FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is
authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments
should be credited to said Deposit Account.

Date: 16 April 2001

Customer No.: 26770

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6057

In re application of:
Application No.:
Filed:

SIFFERT, W.
Not yet assigned
Herewith

Group: Not yet assigned
Examiner: Not yet assigned

Sheet 1 of 1

c872 U.S. PTO
09/836697
04/16/01

FORM PTO-1449

**INFORMATION DISCLOSURE
STATEMENT**

DOCKET NO.: 741135-000010

SERIAL NO.: Not Yet
Assigned

APPLICANT(S): Siffert, W.

FILING DATE: Herewith

GROUP NO.: Not Yet
Assigned

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	INVENTOR/ ASSIGNEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL ATION YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA 1	Cotton, R.G.H. "Current Methods of Mutation Detection" <i>Mutation Research</i> 285:125-144 (1993).
CB 2	Levine et al., "Molecular Cloning of Beta3 Subunit, a Third Form of the G Protein Beta-Subunit Polypeptide" <i>Proc. Natl. Acad. Sci.</i> 87:2329-2333 (1990).
CC 3	Siffert et al., "Enhanced G Protein Activation in Immortalized Lymphoblasts From Patients with Essential Hypertension" <i>J. Clin. Invest.</i> 96:759-766 (1995).
CD 4	Kato et al., "G Protein $\beta 3$ Subunit Variant and Essential Hypertension in Japanese" <i>Hypertension</i> 32:935-938 (1998).
CE 5	Brand et al., "The 825 C/T Polymorphism of the G-Protein Subunit $\beta 3$ Is Not Related to Hypertension" <i>Hypertension</i> 33:1175-1178 (1999).
CF 6	Town, et al., "Alzheimers Disease is not Associated with the Hypertension Genetic Risk Factors PLA ₂ or G Protein $\beta 3$, Either Independently or Interactively with Apolipoprotein E" <i>Amer. J. of Med. Genetics</i> 88:465-468 (1999).
CG 7	Fogarty et al., "The C825T Polymorphism in the Human G-Protein $\beta 3$ subunit gene is not Associated with Diabetic Nephropathy in Type I Diabetes Mellitus" <i>Diabetologia</i> 41:1304-1308 (1998).

EXAMINER:

DATE: